Hello all
If Gmed and Distributors formalise all MOUs into binding agreements, then the future is as follow:
Primza Distribtors
A) INSIDE CHINA
#1
Beijing Silverlake , China
4.05 million units (~U$405 million to U$615 million) over 5 years
Year
Minimum Purchase Quantity:
Year 1 100,000 units (U$10m to $15 million)
Year 2
250,000 units
Year 3
1,000,000 units
Year 4
1,350,000 units
Year 5
1,350,000 units
Total 4,050,000 units
GMV Distribution Agreement for Smartphone Cover in China
09/05/17
https://www.asx.com.au/asxpdf/20170509/pdf/43j49qfmmtw4qt.pdf
B.Sliverlake, website is not available
#2 Shandong Boletong, China
U$65m
430000 to 650000 units,
estimate B2B price at U$100 to U$150 ea
(Unclear if they are for 1,2,3, 4or 5 years?)
https://gmedinnovations.com/asx-announcements/
https://www.asx.com.au/asxpdf/20170727/pdf/43kx57w4gs6g5v.pdf
SDB three hospital/business partners:
Xijing H, Shannxi H, Xiguan H
http://sdboletong.com/index.php?s=/List/index/cid/23.html
How significant are these to SDB business and GMV med-devices?
Beds:
They have a combined >6000 beds for in-patents and surgeries.
vs
Royal Melbourne Hospital has only 570 beds.
How many patients:
They treat >10 million out-pateints in a year, approx the combined population of Sydney/4m, Melbourne/4.5m, Brisbane/2m
How many Primza sensors will they need in future?
B) Primza distributors OUTSIDE CHINA
#3
MEDTL
Cyprus/Greece , U$10.5m
https://www.mymedtl.com
Doctors' testimonials
https://www.mymedtl.com/testimonials
#4
USA, Winolalake , U$10m
http://www.winolalake.com/partners/
Primza
http://www.winolalake.com/software/
GPatch
http://www.winolalake.com/patient-monitoring-and-telemedicine/
#5
India/Taiwan , FCL of UGHL ,
*Yet to be confirmed , re 5/9/18 Asx update *
U$405m , 2.7m units, over 3 years:
Taiwan 0.45m + India 2.25m
= 2.7m units
Y1, U$90m, 600'000 units
Y2, U$135m, 900'000 units
Y3, U$180m, 1200'000 units
Binding MOU for Distribution in India and Taiwan
“UGHL's Tier 1 partners, including Vodafone India, Reliance Communications and BSNL Mobile”
FCL is a subsidiary of UGHL
Subsequent to singing 16/11/17 MOU with GMV , UGHL has moved aggresively expanded into *Aged-care and *Home-care businesses in
China, Japan, Thailand.
https://www.otcmarkets.com/stock/UGHL/news
Note:
1.
HKSE pre revenue biotech IPO
"To qualify for a Hong Kong listing, biotech candidates must have
a market valuation of at least HK$1.5 billion (US$191.13 million) at the time of listing, one “sophisticated” pre-IPO investor,
a product that has passed a phase one clinical trial primarily aimed at showing its safety, and has regulatory approval to begin phase two to prove its efficacy."
2.Nasdaq IPO
http://venturelawcorp.com/listing-requirements-nasdaq/
https://www.investopedia.com/ask/answers/nasdaq-listing-requirements/
3.For 'watchers and wait-ers' only:
i)ST Share prices catalysts :
posts #
34898808 , 34958919
ii)MT to LT potential re-rating events:
posts #,
35287649 ,
34901127 ,
35096870 ,
34910514
iii)HKSE & Nasdaq
post#
35428139 ,
35435633
*Please Dyor before you buy, hold or sell.
Not financial advice.
Aimo.
.
